At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 665 enrolled
Drug / intervention
ALD403 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine
In Brief
A Phase 2 clinical trial evaluating ALD403 and Placebo for Migraine Disorders. Completed, enrolled 665 participants across 92 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesAustralia, Georgia, New Zealand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedOct 2014
Primary CompletionMar 2016
Study CompletionNov 2016
TodayJul 2026
First PostedOct 27, 2014
Enrollment StartOct 1, 2014
Primary CompletionMar 1, 2016
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.7 years ago
Interventions
ALD403biological
Placebobiological